Senores Pharma Capitalizing on CDMO Tailwinds for Global Ascent

Before diving in, you can see how this company is doing now by reading our updated Q2 FY26 performance review — click here.

Senores Pharmaceuticals Limited is a fast-growing pharmaceutical company based in Ahmedabad, Gujarat. Its operations are primarily focused on regulated markets such as the United States, where it develops and markets its own portfolio of generic drugs through Abbreviated New Drug Applications (ANDAs). At the same time, Senores maintains a strong footprint in emerging markets by offering branded generics tailored to local therapeutic needs and regulatory frameworks.

Business model

The company follows a dual business model that combines proprietary product development with contract manufacturing services, commonly referred to as CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization). A key differentiator for the company is its US FDA-approved manufacturing facility located in the United States, which not only enhances credibility in regulated markets but also provides insulation from tariff-related risks and logistical challenges. This unique combination of capabilities positions Senores as a versatile and reliable partner in the global pharmaceutical supply chain, with strong growth prospects in both the B2C and B2B Ssegments.

FY25 financial highlights

Business performance overview

1. Regulated markets (USA & developed countries)

Senores Pharmaceuticals has built a strong ANDA portfolio comprising 61 approved generic products, with 22 already commercialized. These formulations meet rigorous bioequivalence standards, ensuring therapeutic parity with branded drugs — a key requirement in regulated markets like the US. This portfolio was significantly enhanced through the strategic acquisition of 15 ANDAs (14 from Dr. Reddy’s Laboratories and one from Breckenridge) enabling faster market expansion without the time and cost of in-house development. The company maintains a strong EBITDA margin of over 40%, supported by high product quality, US FDA approvals, and efficient operational practices. The company’s strength lies in developing high-quality generic formulations across various therapeutic categories, supported by a US-based, FDA-approved facility that enables rapid scaling and compliance with international quality benchmarks.

2. CDMO/CMO services

Senores Pharmaceuticals has successfully launched 22 commercial products to date, with an additional 69 products in the development pipeline, highlighting its strong growth trajectory. For FY26, the company plans to launch 23 new products under its CDMO/CMO segment, further expanding its presence in contract manufacturing. Additionally, Senores holds certifications from the US Drug Enforcement Administration (DEA) and Barbiturates Authority (BA), enabling it to manufacture and supply controlled substances (a specialized and tightly regulated category) in the US market. This certification not only enhances its credibility but also opens up opportunities in high-entry-barrier therapeutic segments.

3. Emerging markets

Senores Pharmaceuticals is undergoing aggressive expansion, with 48 new product registrations in Q4 alone, bringing the total to 285, and aiming to cross 650 registrations by FY27. The company reported a remarkable growth in income, reaching ₹121 crores in FY25, underscoring its accelerating momentum. While the current EBITDA margin in emerging markets stands at approximately 7%, it is expected to improve significantly in FY26, driven by scale and operational efficiencies. Senores is also refining its go-to-market strategy by focusing on niche molecules and optimizing its commercial approach to enhance growth and profitability in the coming years.

Revenue mix

The revenue mix of Senores Pharmaceuticals reflects a gradual diversification across markets. While regulated markets remained the primary revenue contributor, accounting for 53.5% In contrast, emerging markets gained momentum, increasing their contribution from 20.6% in FY24 to 29.5% in FY25.This shift highlights the company’s expanding footprint in emerging regions while retaining a strong base in regulated markets.

Industry outlook

The global pharmaceutical market (which includes all types of medicines) is growing strongly. It is expected to increase from USD 1,635 billion in 2023 to USD 2,251 billion by 2028. That’s a growth rate of 6.6% per year.

Both branded (innovator) drugs and generic medicines are helping this market grow. But generic drugs are becoming more important because:

• They cost less

• Many branded drug patents are expiring

Regulated markets: Where the growth is happening

Regulated markets like the US and Europe (which have strict quality and safety standards) are leading the way in the global pharma industry.

Market share by 2028

Why regulated markets are growing:

Big investments in research and new treatments have led to strict quality regulations, which in turn allow for higher drug prices. However, in an effort to reduce overall healthcare costs, governments are increasingly encouraging the use of generic drugs.

Because healthcare is expensive in the U.S., more individuals and hospitals are turning to these cost-effective alternatives. As a result, the U.S. generic drug market is projected to reach USD 114 billion.

Emerging markets are expected to grow at a 7.5% CAGR, outpacing developed markets. Their combined value is set to rise from USD 376.3 billion in 2023 to USD 541.0 billion by 2028. Key growth drivers include:

• Expanding population and disease burden

• Improved healthcare infrastructure

• Government investments and reforms

Notably, India is one of the fastest-growing pharma markets, expected to touch USD 37.9 billion by 2028. The Indian market is largely generic-driven, with 96% of drug consumption coming from generics. Oral solids dominate, accounting for over 69% of the Indian pharma dosage segment.

Growth drivers across the industry

• Aging population: The number of people over 60 is set to double by 2050, increasing demand for age-related treatments.

• Chronic diseases: Nearly 1 in 3 adults suffers from multiple chronic conditions, pushing long-term drug demand.

• R&D investments: Ongoing innovation to treat both prevalent and rare diseases.

• Consumer awareness: Post-COVID, demand for preventive and wellness-related drugs has surged.

Insurance penetration and government support in developing nations are driving access to essential medications.

The global pharmaceutical industry is poised for robust growth, underpinned by innovation in regulated markets and expanding access in emerging regions. As demand for both advanced and affordable therapies rises, markets like India are becoming increasingly integral to global pharma supply chains, particularly in generics. Stakeholders focusing on innovation, affordability, and regulatory compliance are likely to benefit the most in the years ahead.

Senores’ operational developments

Senores Pharmaceuticals is actively scaling its manufacturing capabilities, with two production lines currently operational and two additional lines under development to support increasing demand and product launches. While the company experienced some delays in Q4 launches, it anticipates a strong recovery in the second half of FY26 (September–October), with several key product approvals and launches expected during this period. This expansion and upcoming launch momentum are expected to significantly enhance its market presence and drive future revenue growth.

Growth drivers and strategic priorities

Senores Pharmaceuticals is poised for growth, supported by a strong pipeline of 31 ANDA products and 23 CDMO/CMO launches planned over the near term. To meet rising demand, the company is expanding its manufacturing capacity by adding new production lines. Its focus on niche, higher-margin products, particularly in emerging markets, is expected to further enhance profitability.

On the strategic front, Senores is pursuing a dual approach. It aims to drive organic growth through effective pipeline execution and deeper market penetration, while also exploring inorganic opportunities through potential acquisitions in the US and other priority geographies to accelerate its global footprint.

Key strengths of Senores Pharma

• Strong YoY performance across income and margins

• Balanced business model (own products + contract manufacturing)

• Diversified market base (regulated + emerging)

• UUS-based FDA-approved facility adds credibility, facilitates government contracting, and ensures compliance with stringent regulatory standards in global markets.

• Healthy product pipeline ensures future growth visibility

Risks to watch

• Delays in regulatory approvals may affect launch timelines

• Competitive pricing pressure in both markets

• Execution challenges related to capacity expansion and commercialization

Valuation perspective

Net profit estimated assuming tax rate of ~25% on PBT, other income and costs assumed stable

Interpretation:

If Senores delivers on its growth guidance, the stock's P/E ratio could reduce to 19.6 by FY 27 from 40.8 making the current valuation appear more reasonable relative to earnings growth potential.
Senores Pharmaceuticals has delivered an exceptional FY25, with nearly doubling income and a significant margin improvement. Its strong pipeline, expanding manufacturing base, and clear strategic direction put it in a strong position for sustained growth. With a focus on high-value markets, niche products, and cost-effective operations, Senores is building a solid foundation for long-term success in the pharmaceutical industry.

Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.

©️ 2025 — Tradejini. All Rights Reserved.